Investor Alert
Amarin Receives FDA Approval of VASCEPA® (icosapent ethyl) to Reduce Cardiovascular Risk
See Press Release Here
Updated Label Information

DISCOVER

VASCEPA®

EXPERIENCED

in lipid science

INVESTOR

relations

VASCEPA®

LIPID SCIENCE

investor relations

welcome


therapeutics to improve cardiovascular health

Amarin Corporation plc is a rapidly growing, innovative pharmaceutical company focused on developing and commercializing therapeutics to cost-effectively improve cardiovascular health. Amarin’s lead product, VASCEPA® (icosapent ethyl) capsules, is available by prescription in the United States and an increasing number of other countries.

The History of VASCEPA®


Development of VASCEPA® leveraged Amarin’s extensive experience in the therapeutic benefits of polyunsaturated fatty acids and lipid science. The development of VASCEPA® challenged previously established understandings of the treatment of complex disease states and created an important new drug with the potential to significantly improve patient care for millions of patients. The use of VASCEPA® is supported by over 200 issued patents worldwide. VASCEPA® was designated by FDA as a new chemical entity in recognition of the drug’s novel single active ingredient. Similar designations have also been granted to VASCEPA®’s active ingredient in other jurisdictions internationally.

MORE

recent news


Mar 31, 2020

Amarin Highlights VASCEPA® (Icosapent Ethyl)-Related Data Presented at American College of Cardiology’s Annual Scientific Session Together With World Congress of Cardiology (ACC.20/WCC) MORE

Mar 30, 2020

Amarin Comments on Ruling in VASCEPA® ANDA Litigation MORE

Stock Information

Symbol:
AMRN (NASDAQ)
Quote:
$4.00
Change:
-9.58
Date:
4:00 PM on Mar 31, 2020
(latest end of day stock price)
Investor
Relations
Executive
Team
Career
Opportunities
FAQs
Contact
Amarin

Amarin
Corporation

therapeutics to improve
cardiovascular health.

Join Our Mailing List

You may automatically receive Amarin Corporation plc financial information by email.


Click To Subscribe